# Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

> **NCT06874257** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 20 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)

## Interventions

- **BIOLOGICAL:** Laboratory tests and in vitro studies

## Key facts

- **NCT ID:** NCT06874257
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874257, "Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06874257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*